Clinical Trials · NCT06001762
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 90
- Start date
- Oct 2023
- Locations
- 12 sites, United States
- Primary endpoint
- Composite Adverse Rate at 3 months